Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124391 | 1.00 | BACE1 (0.37) | BACE1BACE2CTSDLMNAPKM | |
| SCHEMBL15124987 | 0.88 | BACE1 (0.32) | BACE1BACE2CTSD | |
| SCHEMBL15124988 | 0.88 | BACE1 (0.32) | BACE1BACE2CTSD | |
| SCHEMBL15124614 | 0.76 | BACE1 (0.36) | BACE1BACE2CTSD | |
| SCHEMBL15124615 | 0.76 | BACE1 (0.36) | BACE1BACE2CTSD | |
| SCHEMBL14903798 | 0.75 | BACE1 (0.35) | BACE1BACE2CTSDLMNAPKM | |
| SCHEMBL883225 | 0.73 | BACE1 (0.41) | BACE1BACE2CTSD | |
| SCHEMBL876987 | 0.68 | ABCC9 (0.35) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12496731 | 0.67 | BACE1 (0.34) | BACE1BACE2 | |
| SCHEMBL10081942 | 0.67 | BACE1 (0.34) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619207-B1 | 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2619207-B1 | 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-12 | — | — | EP | disclosed |
| US-8609660-B2 | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-17 | — | — | US | disclosed |
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012038438-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885CTSD 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.